SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : IMNR - Immune Response -- Ignore unavailable to you. Want to Upgrade?


To: Tom Genna who wrote (1179)11/24/1998 8:54:00 AM
From: Emec  Respond to of 1510
 
Immune Response says drug helps arthritis

Reuters Story - November 24, 1998 08:25
CARLSBAD, Calif., Nov 24 (Reuters) - Immune Response Corp. said on Tuesday that its IR501 Therapeutic Vaccine was found to improve treatment of arthritis in patients receiving Incomplete Freund's Adjuvant (IFA), compared with patients receving IFA alone.

The results from the Phase II trial appeal in a paper titled "T Cell Receptor Peptide Vaccination in Rheumatoid Arthritis: A Placebo-Controlled Trial Using a Combination of Vb3, Vb14, and Vb 17," which was published in the November 1998 issue of Arthritis & Rheumatism.




To: Tom Genna who wrote (1179)11/24/1998 8:55:00 AM
From: Emec  Read Replies (1) | Respond to of 1510
 
It is not PR News decision it is IMNR that sends them the story to put out. It is announcing the publication of the results in a journal and the fact that phase 2B will be released before year end